The clinical and prognostic relevance of many recently identified driver gene mutations in
adult acute myeloid leukemia (AML) is poorly defined. We sequenced the coding regions or …

Early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) is a high-risk subgroup of T-lineage
ALL characterized by specific stem cell and myeloid features. In adult ETP-ALL, no …

The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk stratification
of acute myeloid leukemia have been widely adopted, but have not yet been validated in …

Philadelphia-like B-cell precursor acute lymphoblastic leukemia (Ph-like ALL) is characterized
by distinct genetic alterations and inferior prognosis in children and younger adults. The …

Cytogenetically normal acute myeloid leukemia (CN-AML) with biallelic CEBPA gene mutations
(biCEPBA) represents a distinct disease entity with a favorable clinical outcome. So far, …

Some patients with acute myeloid leukemia (AML) who are in complete remission after
induction chemotherapy harbor persisting pre-leukemic clones, carrying a subset of leukemia-…

… Greif, 1, 2 Nikola P. Konstandin, 1, 2 Klaus H. Metzeler, 1 Tobias Herold, 1 Zlatana
Pasalic, 1 Bianka Ksienzyk, 1 Annika Dufour, 1 Friederike Schneider, 1 Stephanie …

A cute myeloid leukemia is a disease of the elderly (median age at diagnosis, 65–70 years).
The prognosis of older acute myeloid leukemia patients is generally poor. While genetic …

Antibody-based immunotherapy is a promising strategy for targeting chemoresistant leukemic
cells. However, classical antibody-based approaches are restricted to targeting lineage-…

Primary therapy resistance is a major problem in acute myeloid leukemia treatment. We set
out to develop a powerful and robust predictor for therapy resistance for intensively treated …